Other languages Jiangsu Hengrui Medicine Co., Ltd.

Equities

600276

CNE0000014W7

End-of-day quote Shanghai S.E. Other stock markets 03:30:00 30/04/2024 am IST			5-day change	1st Jan Change
46.16 ^CNY	-0.04%		+4.20%	+2.06%

26/04	Hengrui Pharma Gets Nod to Trial Insulin Aspart Injection; Shares Up 3%	MT
17/04	Jiangsu Hengrui Medicine Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Hengrui Pharma Gets Nod to Trial Insulin Aspart Injection; Shares Up 3%	26/04
Jiangsu Hengrui Medicine Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	17/04
Jiangsu Hengrui Medicine Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	17/04
Hengrui Pharma's Units Get Nod to Trial Four Cancer Drugs	11/04
China Approves Clinical Trials for Hengrui Pharmaceuticals' Lupus, Asthma Drugs	10/04
Hengrui Pharma's Units Get Approval to Trial Two Gastric Cancer Drugs	09/04
Hengrui Pharma Gets Nod for Injectable Cancer Drug Trial	27/03
Hengrui Pharma Gets Green Light to Trial Four Cancer Drugs	19/03
China stocks steady, helped by biotech rally; Wuxi Apptec drags Hong Kong shares	14/03
Hengrui Pharma Gets Green Light to Trial Tumor Drug Combination	01/03
Hengrui Pharma Gets China Nod to Trial Combo Treatment for Breast Cancer	28/02
US FDA Gives Fast Track Designation to Hengrui Pharma's Lymphoma Drug	23/02
Hengrui Pharma's Unit Gets Nod to Trial Adebelimab Injection	23/02
GSK completes acquisition of Aiolos Bio for up to $1.4 bln	15/02
Jiangsu Hengrui Pharmaceuticals Co., Ltd.'s Commercial Launch of Vivjoa (Oteseconazole) Capsules for the Treatment of Severe Vulvovaginal Candidiasis in China	07/02
MÄRKTE ASIEN/Börsen in China von staatlichen Maßnahmen gestützt	06/02
MÄRKTE ASIEN/China-Börsen von staatlichen Maßnahmen gestützt	06/02
Cancer Drug of Hengrui Pharmaceuticals' Unit Placed in China's List of Breakthrough Therapy Drugs; Shares Climb 4%	05/02
Hengrui Pharmaceuticals Gets Nod for Taglidine Fumarate Injection	01/02
Hengrui Pharmaceuticals' Subsidiary Gets US FDA's Nod for Tacrolimus Capsules	30/01

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Jiangsu Hengrui Medicine Co., Ltd.

Equities

600276

CNE0000014W7

Other languages

Filters